Media Coverage

Quest Diagnostics reported Tuesday a 7 percent year-over-year increase in its Q4 2025 revenue. Revenue for the three months ended Dec. 31, 2025, was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion. Requisition volumes rose 9 percent during the quarter while revenue per requisition fell less than 1 percent. Organic requisition volume rose 8 percent year over year, the Secaucus, New Jersey-based company said.

Forever chemicals. They’re everywhere — from non-stick pans to seafood to cosmetics. 25 Investigates worked with Quest Diagnostics, which offers a PFAS blood panel that screens for nine common forever chemicals for $350. Quest allowed us to film most of my blood test. We went in before the lab opened one January morning to protect patient privacy. Kavanaugh found the test itself to be quick and painless — just one vial of blood. Quest says it began offering the PFAS blood test in 2024. Quest says theirs is the first PFAS blood test available as a consumer-initiated test with physician oversight based on recommendations by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations.

Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.

As Quest Diagnostics President and CEO Jim Davis noted at the 44th Annual JP Morgan Healthcare Conference last week, the RESULTS Act still needed to go through markup in a House subcommittee, then receive consideration in the Senate, undergo a technical feasibility assessment by the US Centers for Medicare and Medicaid Services, and then receive a score from the Congressional Budget Office. "That's a lot of work to be done in 18 days," he said. Davis added, however, that he is "optimistic that the RESULTS Act will get passed in 2026" and that Congress will pass a temporary delay as long as the RESULTS Act is making progress toward passage.

Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health. The lab giants, in separate agreements announced Thursday, Jan. 8, have added Visby Medical’s newly approved, fully at-home PCR test for sexually transmitted infections to their lineup of direct-to-consumer women’s health offerings.

Southfield, Mich.-based Corewell Health and Secaucus, N.J.-based Quest Diagnostics have finalized a lab joint venture and hospital lab management agreement. Quest Diagnostics and Corewell Health’s existing labs will continue to provide services to the joint venture until a 100,000-square-foot centralized lab at the Corewell Health Southfield Center opens in the first quarter of 2027. The new facility will feature advanced diagnostic technologies, including high-throughput molecular testing and automated microbiology.

Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year — and much of the testing, processing and logistics of those samples runs largely unseen through Tampa Bay.

AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026. Cardiometabolic testing is one example, where labs are being asked to look beyond single endpoints. “In 2025, we saw many individuals focus on weight loss as a means of potentially improving their cardiometabolic health,” says Mouris Saghir, PhD, vice president and general manager for cardiometabolic, endocrine, and wellness at Quest Diagnostics.